Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis

Clinical Breast Cancer

Volumn 11, Issue 3, 2011, Pages 177-183

  Hatoum, Hind T ^a,b   Lin, Swu Jane ^a,b   Smith, Matthew R ^c   Guo, Amy ^d   Lipton, Allan ^e  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Hind T Hatoum and Company   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Bone fractures; Breast neoplasms; Complications; Neoplasm metastasis; Outcome assessment; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; FRACTURE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; BONE TUMOR; BREAST TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS;

ADULT; AGED; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 80053402464     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.03.015     Document Type: Article

References (26)

1. American Cancer Society. Cancer Facts and Figures 2010. American Cancer Society; 2010:1-66.
2. Coleman R. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 2007; 7(suppl 1):S29-35. (Pubitemid 47325657)
3. Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 2006; 3:143-53. (Pubitemid 44022751)
4. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006; 4:341-7. (Pubitemid 44420137)
5. Jacobson AF, Shapiro CL, Van den Abbeele AD, et al. Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinoma. Cancer 2001; 91:17-24. (Pubitemid 32052609)
6. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21:4042-57.
7. Coleman RE. Management of bone metastases. Oncologist 2000; 5:463-70.
8. Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 2008; 68:507-34. (Pubitemid 351342020)
9. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23:3314-21.
10. Lipton A, Cook RJ, Major P, et al. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007; 12:1035-43. (Pubitemid 350007015)
11. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113:193-201. (Pubitemid 351976401)
12. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360:679-91.
13. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; CD003474.
14. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008; 113:1438-45.
15. Zometa® (zoledronic acid) [prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/Zometa.pdf.
16. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83. (Pubitemid 17055592)
17. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43: 1130-9. (Pubitemid 41587600)
18. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17:2265-81. (Pubitemid 28466823)
19. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168:49-53. (Pubitemid 37046632)
20. Giordano SH, Fang S, Duan Z, et al. Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 2008; 13:494-502. (Pubitemid 351872867)
21. Aviles A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24:227-30. (Pubitemid 350135975)
22. Daubine F, Le GC, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99:322-30. (Pubitemid 47073494)
23. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13:4482-6. (Pubitemid 47219717)
24. Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-34. (Pubitemid 32448513)
25. Neville-Webbe HL, Evans CA, Coleman RE, et al. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27:92-103.
26. Vogt U, Bielawski KP, Bosse U, et al. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12:1109-14.